From Weight Loss to Liver Normalization: A Deep Dive Into the SYNCHRONIZE-1 Trial Results

In 'From Weight Loss to Liver Normalization: A Deep Dive Into the SYNCHRONIZE-1 Trial Results,' Mazen Noureddin, MD, MHSc, FAASLD delves into the following critical questions:

The SYNCHRONIZE-1 trial has just announced data at the latest ADA Scientific Session. Before we discuss the data, can you provide a brief overview of the study objectives, design, and patient baseline characteristics?

The SYNCHRONIZE-1 data shows an average of 16% weight loss, with liver fat reduction up to 63%. How should clinicians interpret these findings, especially compared to existing pharmacologic options?

The SYNCHRONIZE-1 trial was a Phase III double-blind study in which patients with elevated BMI were randomized in a one-to-one-to-one ratio to placebo, 3.6 mg, or 6.6 mg of survodutide alongside lifestyle counseling, with the primary endpoint of at least 5% weight loss at week 76. Noureddin characterized the SYNCHRONIZE-1 trial design as rigorous, noting investigators held patients to a particularly high standard in terms of dose management, leading him to believe the drug's full weight loss potential may actually exceed the average observed. He also provided a detailed interpretation of the hepatic findings from the SYNCHRONIZE-MASLD sub-study published in Nature Medicine, highlighting that approximately 84% of treated patients achieved a 30% or greater reduction in liver fat by MRI, compared to just 24% on placebo, with 75% achieving a 50% or greater reduction, ~55% achieving a 70% or greater reduction, and 61% of participants achieving normalization of liver fat to below 5%. Noureddin further contextualized the visceral fat findings, a 34% reduction on average, alongside the favorable lean mass preservation of approximately 10 to 11% tissue loss, arguing that the quality of weight loss achieved with survodutide, with fat loss predominating over lean mass loss, is a meaningful clinical differentiator and a strong signal that this agent's effects extend beyond simple caloric reduction to produce a holistic metabolic and hepatic benefits.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Translating SYNCHRONIZE-1 to Practice: Who May Benefit From Dual GLP-1/Glucagon Receptor Agonism?' features Mazen Noureddin advancing his conversation on obesity and MASH and focusing on how the weight loss and liver fat reduction data from SYNCHRONIZE-1 may translate into improved patient outcomes pending FDA approval of survodutide.